 |
Daewoong Pharmaceutical |
[Alpha Biz= Reporter Kim Jisun] Daewoong Pharmaceutical announced on the 19th that it will launch its botulinum toxin 'NUCEIVA' in Spain through its partner 'Evolus'.
With this, Daewoong Pharmaceutical's botulinum toxin has expanded its presence in Europe to a total of five countries: the UK, Germany, Austria, Italy, and now Spain. Europe is the second-largest botulinum toxin market after the United States.
Evolus, Daewoong Pharmaceutical's partner, will handle the distribution and marketing of NUCEIVA in Spain. They plan to support the rapid market penetration of NUCEIVA by offering various training programs for local healthcare professionals and providing online platforms.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
